Literature DB >> 15723436

Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease.

Shiobhan R Weston1, Wendy Leyden, Rose Murphy, Nathan M Bass, Beth P Bell, M Michele Manos, Norah A Terrault.   

Abstract

We performed a cross-sectional study of newly diagnosed cases of nonalcoholic fatty liver disease (NAFLD) identified between December 1998 and December 2000 in the Chronic Liver Disease Surveillance Study. We compared the demographic and clinical features of NAFLD in a racially diverse representative U.S. population (Alameda County, CA). Diagnostic criteria for probable NAFLD were persistent unexplained elevation of serum aminotransferase levels, radiology (ultrasound or computed tomography scan) consistent with fatty liver, and/or two or more of the following: (i) body mass index of 28 kg/m(2) or more, (ii) type 2 diabetes, or (iii) hyperlipidemia, in the absence of significant alcohol use. Definite NAFLD cases required histological confirmation. Of the 742 persons with newly diagnosed chronic liver disease, 159 (21.4%) had definite or probable NAFLD. The majority were nonwhite: Hispanics (28%), Asians (18%), African Americans (3%), and other race(s) (6%). African Americans with NAFLD were significantly older than other racial or ethnic groups (P < .001), and in Asians, NAFLD was 3.5 times more common in males than in females (P = .016). Clinical correlates of NAFLD (obesity, hyperlipidemia, diabetes) were similar among racial and ethnic groups, except that body mass index was lower in Asians compared with other groups (P < .001). Compared with the base population (Kaiser Permanente members), Hispanics with NAFLD were overrepresented (28% vs. 10%) and whites were underrepresented (45% vs. 59%). In conclusion, these racial and gender variations may reflect differences in genetic susceptibility to visceral adiposity, including hepatic involvement, and may have implications for the evaluation of persons with the metabolic syndrome. Clinicians need to be aware of the variable presentations of NAFLD in different racial and ethnic groups.

Entities:  

Mesh:

Year:  2005        PMID: 15723436     DOI: 10.1002/hep.20554

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  108 in total

Review 1.  Histopathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

2.  Hepatobiliary quiz-3 (2012).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2012-09

3.  Donor race does not predict graft failure after liver transplantation.

Authors:  Sumeet K Asrani; Young-Suk Lim; Terry M Therneau; Rachel A Pedersen; Julie Heimbach; W Ray Kim
Journal:  Gastroenterology       Date:  2010-02-19       Impact factor: 22.682

4.  Treatment options for nonalcoholic fatty liver disease.

Authors:  Brian Lam; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

5.  Predictors of cirrhosis in Hispanic patients with nonalcoholic steatohepatitis.

Authors:  Waleed M Alazmi; Arie Regev; Enrique G Molina; Eugene R Schiff
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

6.  Probable NAFLD, by ALT levels, and diabetes among Filipino-American women.

Authors:  Charlene A Wong; Maria Rosario G Araneta; Elizabeth Barrett-Connor; John Alcaraz; Donna Castañeda; Carol Macera
Journal:  Diabetes Res Clin Pract       Date:  2007-08-30       Impact factor: 5.602

7.  Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity.

Authors:  Nazarii Kobyliak; Tetyana Falalyeyeva; Petro Bodnar; Tetyana Beregova
Journal:  Probiotics Antimicrob Proteins       Date:  2017-06       Impact factor: 4.609

8.  Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.

Authors:  Yvonne N Flores; Rafael Velázquez-Cruz; Paula Ramírez; Manuel Bañuelos; Zuo-Feng Zhang; Hal F Yee; Shen-Chih Chang; Samuel Canizales-Quinteros; Manuel Quiterio; Guillermo Cabrera-Alvarez; Nelly Patiño; Jorge Salmerón
Journal:  Mol Biol Rep       Date:  2016-10-17       Impact factor: 2.316

Review 9.  Managing nonalcoholic fatty liver disease: recommendations for family physicians.

Authors:  Ignazio Grattagliano; Piero Portincasa; Vincenzo O Palmieri; Giuseppe Palasciano
Journal:  Can Fam Physician       Date:  2007-05       Impact factor: 3.275

Review 10.  NAFLD in Asia--as common and important as in the West.

Authors:  Geoffrey C Farrell; Vincent Wai-Sun Wong; Shiv Chitturi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.